Increased plasma levels of sHLA-G have also been described in a plethora of solid tumors such as cutaneous melanoma, glioblastoma multiforme, esophageal squamous cell carcinoma, non-small cell lung cancer, ovary10 and colorectal cancer22, among others, in correlation with an adverse prognosis and tumor immune evasion, since HLA-G has inhibitory effects on all immune cells, and by inducing Treg cells14–23. This evidence concerns the gene HLA-G and non-small cell lung carcinoma.